Get the Stockscreener App
7.30
5.49%
0.38
After Hours:
7.35
0.05
+0.68%
Alumis Inc stock is traded at $7.30, with a volume of 2.42M.
It is up +5.49% in the last 24 hours and up +57.33% over the past month.
Alumis Inc is a clinical-stage biopharmaceutical company focused on identifying, acquiring, and accelerating the development and commercialization of transformative medicines for autoimmune disorders. The Company leverages its proprietary precision data analytics platform, biological insights, and a team of experts with deep experience in precision medicine drug discovery, development, and immunology, to create medicines that significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Company pipeline includes: ESK-001, TYK2, A-OO5, IRF5.
See More
Previous Close:
$6.92
Open:
$6.85
24h Volume:
2.42M
Relative Volume:
3.31
Market Cap:
$709.62M
Revenue:
-
Net Income/Loss:
$-238.77M
P/E Ratio:
-0.2723
EPS:
-26.808
Net Cash Flow:
$-216.62M
1W Performance:
+32.25%
1M Performance:
+57.33%
6M Performance:
+52.72%
1Y Performance:
-22.67%
1-Day Range:
$6.67
$7.75
1-Week Range:
$5.44
$7.75
52-Week Range:
$2.7601
$10.49
Alumis Inc Stock (ALMS) Company Profile
Name
Alumis Inc
Sector
Industry
Phone
650-231-6625
Address
280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO
Compare ALMS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALMS
Alumis Inc
|
7.30 | 722.40M | 0 | -238.77M | -216.62M | -26.81 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.76 | 107.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
755.90 | 77.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
436.38 | 58.90B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
918.92 | 56.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
198.76 | 42.58B | 447.02M | -1.18B | -906.14M | -6.1812 |
Alumis Inc Stock (ALMS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-25-25 | Initiated | Wells Fargo | Overweight |
| Jun-10-25 | Resumed | Guggenheim | Buy |
| Jan-30-25 | Initiated | Oppenheimer | Outperform |
| Oct-31-24 | Initiated | Robert W. Baird | Outperform |
| Oct-17-24 | Initiated | H.C. Wainwright | Buy |
| Jul-23-24 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-23-24 | Initiated | Guggenheim | Buy |
| Jul-23-24 | Initiated | Leerink Partners | Outperform |
| Jul-23-24 | Initiated | Morgan Stanley | Overweight |
View All
Alumis Inc Stock (ALMS) Latest News
How Alumis Inc. stock performs in rising dollar environmentEarnings Trend Report & Precise Swing Trade Entry Alerts - newser.com
Insider Trading Spotlight: Wednesday’s Top Buys and Sells Revealed By Investing.com - Investing.com Australia
Alumis Inc. Stock (ALMS) Opinions on Insider Purchases and Clinical Updates - Quiver Quantitative
Insider Trading Spotlight: Wednesday’s Top Buys and Sells Revealed - Investing.com
Analyzing drawdowns of Alumis Inc. with statistical tools2025 Price Momentum & Weekly High Return Stock Forecasts - newser.com
Alumis Insider Bought Shares Worth $1,529,865, According to a Recent SEC Filing - MarketScreener
Alumis Insider Bought Shares Worth $3,094,725, According to a Recent SEC Filing - MarketScreener
Foresite Labs buys Alumis Inc (ALMS) shares worth $3.09 million By Investing.com - Investing.com Nigeria
Foresite capital funds buy Alumis (ALMS) shares for $3.09 million By Investing.com - Investing.com UK
Foresite capital funds buy Alumis (ALMS) shares for $3.09 million - Investing.com India
Alumis Inc: director Tananbaum buys $3.09 million in ALMS stock By Investing.com - Investing.com Australia
Alumis Inc: director Tananbaum buys $3.09 million in ALMS stock - Investing.com
Alumis Inc (ALMS) director Akkaraju buys shares worth $1.53 million By Investing.com - Investing.com Nigeria
Alumis Inc (ALMS) director Akkaraju buys shares worth $1.53 million - Investing.com
Will Alumis Inc. outperform the marketDividend Hike & Real-Time Stock Entry Alerts - newser.com
Real time scanner hits for Alumis Inc. explainedQuarterly Earnings Summary & Long-Term Capital Growth Strategies - newser.com
Will Alumis Inc. continue its uptrendJuly 2025 Drop Watch & Expert Curated Trade Setup Alerts - newser.com
Hedge Fund and Insider Trading News: Tom Steyer, David Tepper, Davide Leone, Verition Fund Management, Balyasny Asset Management, Alumis Inc (ALMS), and More - Insider Monkey
How to manage a losing position in Alumis Inc.Quarterly Earnings Report & Real-Time Volume Trigger Notifications - newser.com
Amer Sports Posts Upbeat Q3 Earnings, Joins Diginex, James Hardie Industries And Other Big Stocks Moving Higher On Tuesday - Benzinga
Analysts Are Bullish on Top Materials Stocks: Alumis Inc. (ALMS), TMC the metals company Inc. (TMC) - The Globe and Mail
Director Makes a Bold Move with Massive Alumis Inc. Stock Purchase - TipRanks
Alumis Inc: director Akkaraju buys $1.45 million in shares By Investing.com - Investing.com Nigeria
Alumis Insider Bought Shares Worth $1,449,940, According to a Recent SEC Filing - MarketScreener
Alumis Inc: director Akkaraju buys $1.45 million in shares - Investing.com
Dir Akkaraju Buys 276,179 ($1.4M) Of Alumis Inc [ALMS] - TradingView
[Form 4] ALUMIS INC. Insider Trading Activity - Stock Titan
Is a relief rally coming for Alumis Inc. holdersJuly 2025 Setups & Verified Swing Trading Watchlists - newser.com
Will Upcoming ONWARD Data Drive Alumis' Stock Forward? - RTTNews
Alumis reports Q3 revenue $2.07M, consensus $3.14M - MSN
Alumis Inc. Advances Pipeline Amid Financial Challenges - MSN
Alumis Bets Big On R&D Despite Growing Losses - Finimize
Alumis Racks Up Losses But Analysts See Big Upside - Finimize
Biopharmaceutical firm Alumis's Q3 net loss widens - MarketScreener
ALMS: Q3 2025 net loss was $110.8M, with a $187.9M gain from the ACELYRIN Merger and $377.7M in cash - TradingView
[10-Q] ALUMIS INC. Quarterly Earnings Report | ALMS SEC FilingForm 10-Q - Stock Titan
Alumis Inc. Reports Third Quarter 2025 Financial Results and Highlights Key Clinical Development Milestones - Quiver Quantitative
Alumis Reports Third Quarter 2025 Financial Results and Highlights Recent Progress - The Manila Times
[8-K] ALUMIS INC. Reports Material Event | ALMS SEC FilingForm 8-K - Stock Titan
Alumis Inc Stock (ALMS) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.38%
1.42%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):